Marcel G. Smits

Marcel G. Smits

Auto-generated profile, based on publicly available information

Marcel G. Smits

Department of Sleep-wake disorders and Chronobiology, Gelderse Vallei Hospital, Ede 6716 RP, The Netherlands

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2009 in Journal of Pineal Research
Verified
Journal Article
Closed access
PDF file
MHMichel Hoebert
Michel Hoebert
KHKristiaan B. Van Der Heijden
Kristiaan B. Van Der Heijden
IGIngeborg Marianne Van Geijlswijk
Ingeborg Marianne Van Geijlswijk
MSMarcel G. Smits
Marcel G. Smits

1 November 2003 in Journal of the American Academy of Child & Adolescent Psychiatry
Verified
Journal Article
Closed access
MSMarcel G. Smits
Marcel G. Smits
HSHenk F. van Stel
Henk F. van Stel
KHKristiaan van der Heijden
Kristiaan van der Heijden
AMAnne Marie. Meijer
Anne Marie. Meijer
ACAnton M.L. Coenen
Anton M.L. Coenen
GKGerard A. Kerkhof
Gerard A. Kerkhof

2 March 2018 in Healthcare
Verified
Journal Article
Open access
PDF file
TZTom Zwart
Tom Zwart
MSMarcel G. Smits
Marcel G. Smits
TEToine C.G. Egberts
Toine C.G. Egberts
CRCarin M.A. Rademaker
Carin M.A. Rademaker
IGIngeborg Marianne Van Geijlswijk
Ingeborg Marianne Van Geijlswijk
The extent of continuance of melatonin therapy initiated in pre-pubertal children with chronic sleep onset insomnia (CSOI) was investigated in young adult life. Sleep timing, sleep quality, adverse events, reasons for cessation of therapy, and patient characteristics with regard to therapy regimen, chronotype and lifestyle factors possibly influencing sleeping behavior were assessed. With an online survey using questionnaires (Pittsburgh Sleep Quality Index, Insomnia Severity Index, Morningness-Eveningness Questionnaire, and Munich Chronotype Questionnaire), outcomes were measured and compared with age-related controls. These controls were extracted from published epidemiological research programs applying the same questionnaires. At the moment of the survey, melatonin was still continued by 27.3% of the patients, with a mean treatment duration of 10.8 years. The overall average treatment duration was 7.1 years. Sleep quality of both discontinued and persistent melatonin users did not deviate from controls. Sleep timing and chronotype scores indicated evening type preference in all responders. Adverse events were scarce but the perceived timing of pubertal development suggested a tendency towards delayed puberty in former and current users of melatonin. This study may underestimate the number of children that are able to stop using melatonin due to the response rate (47.8%) and appeal for continuing users. Sleep timing parameters were based on self-reported estimates. Control populations were predominantly students and were of varying nationalities. The statistical power of this study is low due to the limited sample size. Melatonin therapy sustained for 7.1 years does not result in substantial deviations of sleep quality as compared to controls and appears to be safe. The evening type preference suggests a causal relation with CSOI. This study shows that ten years after initiation of treatment with melatonin for CSOI, approximately 75% of the patients will have normal sleep quality without medication.

12 January 2006 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
RHR. O. van Heukelom
R. O. van Heukelom
JPJ. B. Prins
J. B. Prins
MSM. G. Smits
M. G. Smits
GBG. Bleijenberg
G. Bleijenberg

2 September 2015 in Behavioral Sleep Medicine
Verified
Journal Article
Closed access
MSMark A. Snitselaar
Mark A. Snitselaar
MSMarcel G. Smits
Marcel G. Smits
JSJan Spijker
Jan Spijker
In this observational cross-sectional study, 49 subjects were assessed for sleep disorders and for ADHD symptoms. Thirty-six received an ADHD diagnosis (29: combined type (ADHD-C); 7: inattentive type). An RLS and RLS symptoms prevalence of 34.5% was found, with a higher prevalence rate in the ADHD-C subgroup, although not significantly (p = 0.066). RLS symptoms were correlated with particularly hyperactivity-impulsivity (ρ = 0.742; p: 0.000). ADHD patients with positive RLS scores reported higher scores on the ADHD-Rating scale compared with patients with negative RLS scores (Z: −2.968, p = 0.003), mainly due to higher hyperactivity-impulsivity scores (Z: −3.145; p = 0.002). Our findings show that clinicians need to be aware of RLS among adult ADHD patients, particularly those with severe hyperactivity-impulsivity symptoms.

1 January 2001 in Clinical Drug Investigation
Verified
Journal Article
Closed access
PDF file
SWS. van Wieringen
S. van Wieringen
TJT. Jansen
T. Jansen
MSM. G. Smits
M. G. Smits
JNJ. E. Nagtegaal
J. E. Nagtegaal
ACA. M. L. Coenen
A. M. L. Coenen